Bico Group AB (publ)

https://www.bico.com

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,850 publications. BICO is listed on Nasdaq Stockholm under BICO. *

	Start	2021-08-12 renamed
	Group	Bico (Group)
	Industry	3D bioprinting
	Industry 2	single cell dispenser
	Person	Forss, Maria (Bico Group 202311– CEO before Vitrolife + AstraZeneca)
	Person 2	Thordenberg, Jacob (Bico 202205 Head of M&A)

	Region	Göteborg (Gothenburg)
	Country	Sweden
	City	n. a.
		Address record changed: 2021-09-23

Basic data	Employees	D: 101 to 500 (2019-08-31)
	Currency	SEK
	Annual sales	105,457,000 (sales, net, consolidated (2018/19) 2019-08-31)
	Profit	581,000 (2019-08-31)
	Cash	198,770,000 (2019-08-31)

		* Document for »About Section«: Bico Group AB. (8/23/21). "Press Release: Dispendix Welcomes Petros Apostolopoulos as New CEO to Strengthen Position as Leading Liquid Handling and Lab Automation Company".

		Record changed: 2023-08-29